A new study has found that a third of cancer drugs given accelerated approval by the U.S. Food and Drug Administration (FDA) continue to be recommended in clinical guidelines after they fail to show any benefit in trials. U.S. and Canadian researchers collaborated on the study, which was published in the British Medical Journal on Sept. 8. The team investigated […]

The post Fast-Tracked Cancer Drugs Still Recommended To Patients Despite Poor Performance In Trials first appeared on The Florida Star | The Georgia Star.